JMERC
Owner
Janbazan Medical and Engineering Research Center (JMERC) is the owner of IJWPH.
0.4
Cite Score
SJR: 0.114 / SNIP: 0.090
Volume 15, Issue 4 (2023)
Iran J War Public Health 2023, 15(4): 447-452 |
Back to browse issues page
Article Type:
Subject:
History
Received: 2024/02/1 | Accepted: 2024/03/4 | Published: 2023/04/15
Received: 2024/02/1 | Accepted: 2024/03/4 | Published: 2023/04/15
How to cite this article
Al-Barqaawi M, Al_Joubouri Z, Ibrahim S. Relationship of Hospitalized COVID-19 Patients and Thyroid Dysfunction. Iran J War Public Health 2023; 15 (4) :447-452
URL: http://ijwph.ir/article-1-1437-en.html
URL: http://ijwph.ir/article-1-1437-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rights and permissions
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
1- Department of Biochemistry, Faculty of Medicine, University of Kufa, Kufa, Iraq
2- Department of Pharmacology and Toxicology, Faculty of Pharmacy, University of Kufa, Kufa, Iraq
3- Department of Clinical Laboratory Sciences, Faculty of Pharmacy, University of Kufa, Kufa, Iraq, Department of Clinical Laboratory Sciences, Faculty of Pharmacy, University of Kufa, Kufa, Najaf Governorate, Iraq. Post Box: 21 (asadsuaad@yahoo.com)
2- Department of Pharmacology and Toxicology, Faculty of Pharmacy, University of Kufa, Kufa, Iraq
3- Department of Clinical Laboratory Sciences, Faculty of Pharmacy, University of Kufa, Kufa, Iraq, Department of Clinical Laboratory Sciences, Faculty of Pharmacy, University of Kufa, Kufa, Najaf Governorate, Iraq. Post Box: 21 (asadsuaad@yahoo.com)
Abstract (471 Views)
Aims: Although vaccines have been developed for COVID-19, the virus continues to present problems to the health sector. The current study assessed thyroid function in all hospitalized patients diagnosed with the virus to ascertain whether COVID-19 infection was linked to thyroid function abnormalities.
Instrument & Methods: An observational cohort study was conducted on all COVID-19-positive patients hospitalized in the Al-Fourat Al-Awsat Hospital in Al-Kufa, Iraq, between September 2021 and April 2022. 208 potential patients were tested during this period, and 150 COVID-19 patients and 50 COVID-19-negative individuals were selected. A sample of blood was collected during hospitalization. A serum was used to determine the thyroid-stimulating hormone.
Findings: Hypertension, shortness of breath, diabetes, liver dysfunction, and cardiac and pro-inflammatory diseases were the most frequent comorbidities in COVID-19 patients. The association between COVID-19 and Control groups indicated a significant difference in age, body mass index, gender, systolic- and diastolic blood pressure, fasting blood sugar, HbA1C, alanine aminotransferase, and aspartate aminotransferase. Also, the analysis indicated a significant (p<0.001) difference between COVID-19 patients and the control group in the level of TSH.
Conclusion: Thyroid impairment is frequent in most individuals admitted to the hospital with a COVID-19 infection. Low thyroid-stimulating hormone level is a reliable indicator of poor prognosis in COVID-19-infected individuals.
Instrument & Methods: An observational cohort study was conducted on all COVID-19-positive patients hospitalized in the Al-Fourat Al-Awsat Hospital in Al-Kufa, Iraq, between September 2021 and April 2022. 208 potential patients were tested during this period, and 150 COVID-19 patients and 50 COVID-19-negative individuals were selected. A sample of blood was collected during hospitalization. A serum was used to determine the thyroid-stimulating hormone.
Findings: Hypertension, shortness of breath, diabetes, liver dysfunction, and cardiac and pro-inflammatory diseases were the most frequent comorbidities in COVID-19 patients. The association between COVID-19 and Control groups indicated a significant difference in age, body mass index, gender, systolic- and diastolic blood pressure, fasting blood sugar, HbA1C, alanine aminotransferase, and aspartate aminotransferase. Also, the analysis indicated a significant (p<0.001) difference between COVID-19 patients and the control group in the level of TSH.
Conclusion: Thyroid impairment is frequent in most individuals admitted to the hospital with a COVID-19 infection. Low thyroid-stimulating hormone level is a reliable indicator of poor prognosis in COVID-19-infected individuals.
Keywords:
Thyroid-Stimulating Hormone [MeSH], Interlukin-6 [MeSH], Nuclear factor-κB [MeSH], D-Dimer [MeSH], COVID-19 [MeSH]
References
1. Boopathi S, Poma AB, Kolandaivel P. Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment. J Biomol Struct Dyn. 2021;39(9):3409-18. [Link] [DOI:10.1080/07391102.2020.1758788]
2. Duployez C, Le Guern R, Tinez C, Lejeune AL, Robriquet L, Six S, et al. Panton-valentine leukocidin-secreting staphylococcus aureus pneumonia complicating COVID-19. Emerg Infect Dis. 2020;26(8):1939-41. [Link] [DOI:10.3201/eid2608.201413]
3. Zhang JM, An J. Cytokines, inflammation, and pain. Int Anesthesiol Clin. 2007;45(2):27-37. [Link] [DOI:10.1097/AIA.0b013e318034194e]
4. Chung S, Lapoint K, Martinez K, Kennedy A, Boysen Sandberg M, McIntosh MK. Preadipocytes mediate lipopolysaccharide-induced inflammation and insulin resistance in primary cultures of newly differentiated human adipocytes. Endocrinology. 2006;147(11):5340-51. [Link] [DOI:10.1210/en.2006-0536]
5. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116(7):1793-801. [Link] [DOI:10.1172/JCI29069]
6. Antunes TT, Gagnon A, Langille ML, Sorisky A. Thyroid-stimulating hormone induces interleukin-6 release from human adipocytes through activation of the nuclear factor-kappaB pathway. Endocrinology. 2008;149(6):3062-6. [Link] [DOI:10.1210/en.2007-1588]
7. Milani AT, Khadem-Ansari MH, Rasmi Y. Effects of thyroid-stimulating hormone on adhesion molecules and pro-inflammatory cytokines secretion in human umbilical vein endothelial cells. Res Pharm Sci. 2018;13(6):546-56. [Link] [DOI:10.4103/1735-5362.245966]
8. Eljilany I, Elzouki AN. D-dimer, fibrinogen, and IL-6 in COVID-19 patients with suspected venous thromboembolism: A narrative review. Vasc Health Risk Manag. 2020;16:455-62. [Link] [DOI:10.2147/VHRM.S280962]
9. Brent GA. Mechanisms of thyroid hormone action. J Clin Invest. 2012;122(9):3035-43. [Link] [DOI:10.1172/JCI60047]
10. Biswas S, Thakur V, Kaur P, Khan A, Kulshrestha S, Kumar P. Blood clots in COVID-19 patients: Simplifying the curious mystery. Med Hypotheses. 2021;146:110371. [Link] [DOI:10.1016/j.mehy.2020.110371]
11. Pirahanchi Y, Toro F, Jialal I. Physiology, thyroid stimulating hormone. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023. [Link]
12. Dong M, Zhang J, Ma X, Tan J, Chen L, Liu S, et al. ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19. Biomed Pharmacother. 2020;131:110678. [Link] [DOI:10.1016/j.biopha.2020.110678]
13. Caron P. Thyroid disorders and SARS-CoV-2 infection: From pathophysiological mechanism to patient management. Ann Endocrinol. 2020;81(5):507-10. [Link] [DOI:10.1016/j.ando.2020.09.001]
14. Chen M, Zhou W, Xu W. Thyroid function analysis in 50 patients with COVID-19: A retrospective study. Thyroid. 2021;31(1):8-11. [Link] [DOI:10.1089/thy.2020.0363]
15. Zou R, Wu C, Zhang S, Wang G, Zhang Q, Yu B, et al. Euthyroid sick syndrome in patients with COVID-19. Front Endocrinol. 2020;11:566439. [Link] [DOI:10.3389/fendo.2020.566439]
16. Muller I, Cannavaro D, Dazzi D, Covelli D, Mantovani G, Muscatello A, et al. SARS-CoV-2-related atypical thyroiditis. Lancet Diabetes Endocrinol. 2020;8(9):739-41. [Link] [DOI:10.1016/S2213-8587(20)30266-7]
17. Lania A, Sandri MT, Cellini M, Mirani M, Lavezzi E, Mazziotti G. Thyrotoxicosis in patients with COVID-19: The THYRCOV study. Eur J Endocrinol. 2020;183(4):381-7. [Link] [DOI:10.1530/EJE-20-0335]
18. Gao W, Guo W, Guo Y, Shi M, Dong G, Wang G, et al. Thyroid hormone concentrations in severely or critically ill patients with COVID-19. J Endocrinol Invest. 2021;44(5):1031-40. [Link] [DOI:10.1007/s40618-020-01460-w]
19. Khoo B, Tan T, Clarke SA, Mills EG, Patel B, Modi M, et al. Thyroid function before, during, and after COVID-19. J Clin Endocrinol Metab. 2021;106(2):e803-11. [Link] [DOI:10.1210/clinem/dgaa830]
20. Lui DTW, Lee CH, Chow WS, Lee ACH, Tam AR, Fong CHY, et al. Thyroid dysfunction in relation to immune profile, disease status, and outcome in 191 Patients with COVID-19. J Clin Endocrinol Metab. 2021;106(2):e926-35. [Link] [DOI:10.1210/clinem/dgaa813]
21. Zhang Y, Lin F, Tu W, Zhang J, Choudhry AA, Ahmed O, et al. Thyroid dysfunction may be associated with poor outcomes in patients with COVID-19. Mol Cell Endocrinol. 2021;521:111097. [Link] [DOI:10.1016/j.mce.2020.111097]
22. Schwarz Y, Percik R, Oberman B, Yaffe D, Zimlichman E, Tirosh A. Sick euthyroid syndrome on presentation of patients with COVID-19: A potential marker for disease severity. Endocr Pract. 2021;27(2):101-9. [Link] [DOI:10.1016/j.eprac.2021.01.001]
23. Campi I, Bulgarelli I, Dubini A, Perego GB, Tortorici E, Torlasco C, et al. The spectrum of thyroid function tests during hospitalization for SARS COV-2 infection. Eur J Endocrinol. 2021;184(5):699-709. [Link] [DOI:10.1530/EJE-20-1391]
24. Malik J, Malik A, Javaid M, Zahid T, Ishaq U, Shoaib M. Thyroid function analysis in COVID-19: A retrospective study from a single center. PloS One. 2021;16(3):e0249421. [Link] [DOI:10.1371/journal.pone.0249421]
25. Carlé A, Andersen SL, Boelaert K, Laurberg P. Management of endocrine disease: Subclinical thyrotoxicosis: Prevalence, causes and choice of therapy. Eur J Endocrinol. 2017;176(6):R325-37. [Link] [DOI:10.1530/EJE-16-0276]
26. Clausen CL, Rasmussen ÅK, Johannsen TH, Hilsted LM, Skakkebæk NE, Szecsi PB. Thyroid function in COVID-19 and the association with cytokine levels and mortality. Endocr Connect. 2021;10(10):1234-42. [Link] [DOI:10.1530/EC-21-0301]
27. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. Jama. 2020;324(8):782‐93. [Link] [DOI:10.1001/jama.2020.12839]
28. Osuchowski MF, Winkler MS, Skirecki T, Cajander S, Shankar-Hari M, Lachmann G, et al. The COVID-19 puzzle: Deciphering pathophysiology and phenotypes of a new disease entity. Lancet Respir Med. 2021;9(6):622‐42. [Link] [DOI:10.1016/S2213-2600(21)00218-6]
29. Conte G, Cei M, Evangelista I, Colombo A, Vitale J, Mazzone A, et al. The meaning of D-dimer value in COVID-19. Clin Appl Thromb Hemost. 2021;27:10760296211017668. [Link] [DOI:10.1177/10760296211017668]
30. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395(10229):1054‐62. [Link] [DOI:10.1016/S0140-6736(20)30566-3]
31. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72314 cases from the Chinese center for disease control and prevention. Jama. 2020;323(13):1239‐42. [Link] [DOI:10.1001/jama.2020.2648]
32. Yao Y, Cao J, Wang Q, Shi Q, Liu K, Luo Z, et al. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: A case control study. J Intensive Care. 2020;8:49. [Link] [DOI:10.1186/s40560-020-00466-z]
33. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. ISTH Interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023‐6. [Link] [DOI:10.1111/jth.14810]
34. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and thrombotic or thromboembolic disease: Implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(23):2950‐73. [Link] [DOI:10.1016/j.jacc.2020.04.031]
35. Rostami M, Mansouritorghabeh H. D-dimer level in COVID-19 infection: A systematic review. Expert Rev Hematol. 2020;13(11):1265‐75. [Link] [DOI:10.1080/17474086.2020.1831383]
36. Poudel A, Poudel Y, Adhikari A, Aryal BB, Dangol D, Bajracharya T, et al. D-dimer as a biomarker for assessment of COVID-19 prognosis: D-dimer levels on admission and its role in predicting disease outcome in hospitalized patients with COVID-19. PLoS One. 2021;16(8):e0256744. [Link] [DOI:10.1371/journal.pone.0256744]
37. Soni M, Gopalakrishnan R, Vaishya R, Prabu P. D-dimer level is a useful predictor for mortality in patients with COVID-19: Analysis of 483 cases. Diabetes Metab Syndr. 2020;14(6):2245‐9. [Link] [DOI:10.1016/j.dsx.2020.11.007]
38. Naymagon L, Zubizarreta N, Feld J, Van Gerwen M, Alsen M, Thibaud S, et al. Admission D-dimer levels, D-dimer trends, and outcomes in COVID-19. Thromb Res. 2020;196:99‐105. [Link] [DOI:10.1016/j.thromres.2020.08.032]
39. He X, Yao F, Chen J, Wang Y, Fang X, Lin X, et al. The poor prognosis and influencing factors of high D-dimer levels for COVID-19 patients. Sci Rep. 2021;11(1):1830. [Link] [DOI:10.1038/s41598-021-81300-w]
40. Lv LF, Jia HY, Zhang HF, Hu YX. Expression level and clinical significance of IL-2, IL-6 and TGF-β in elderly patients with goiter and hyperthyroidism. Eur Rev Med Pharmacol Sci. 2017;21(20):4680-6. [Link]
41. Velavan TP, Meyer CG. Mild versus severe COVID-19: Laboratory markers. Int J Infect Dis. 2020;95:304-7. [Link] [DOI:10.1016/j.ijid.2020.04.061]
42. Kim BW. Critically Ill COVID-19 patients may be prone to subacute thyroiditis. Clin Thyroidol. 2020;32(9):412-4. [Link] [DOI:10.1089/ct.2020;32.412-414]
43. Mohmed HA. Measurement of D-Dimer Levels in hyperthyroidism patients. Open Access Libr J. 2016;3(8):1-5. [Link] [DOI:10.4236/oalib.1102772]
44. Lazartigues E, Qadir MMF, Mauvais-Jarvis F. Endocrine significance of SARS-CoV-2's reliance on ACE2. Endocrinology. 2020;161(9):bqaa108. [Link] [DOI:10.1210/endocr/bqaa108]